Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

van de Donk, Niels ^{[1
]}

Moreau, Philippe ^{[2
]}

Garfall, Alfred ^{[3
]}

Bhutani, Manisha ^{[4
]}

Oriol, Albert ^{[5
,6
]}

Nooka, Ajay ^{[7
]}

Martin, Thomas ^{[8
]}

Rosinol, Laura ^{[9
]}

Mateos, Maria-Victoria ^{[10
]}

Bahlis, Nizar ^{[11
]}

Popat, Rakesh ^{[12
]}

Besemer, Britta ^{[13
]}

Martinez Lopez, Joaquin ^{[14
]}

Krishnan, Amrita ^{[15
]}

Delforge, Michel ^{[16
]}

Trancucci, Danielle ^{[17
]}

Verona, Raluca ^{[18
]}

Stephenson, Tara ^{[18
]}

Chastain, Katherine ^{[17
]}

Sidana, Surbhi ^{[19
]}

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[2] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[4] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[10] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[12] NHS Fdn Trust, Univ Coll London Hosp, London, England

[13] Univ Tubingen, Tubingen, Germany

[14] Hematol Hosp 12 Octubre, Madrid, Spain

[15] City Hope Comprehens Canc Ctr, Duarte, CA USA

[16] Univ Leuven, Leuven, Belgium

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Stanford Univ, Sch Med, Stanford, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

relapsed/refractory multiple myeloma; bispecifics; multiple myeloma; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-163

引用

页码：S477 / S478

页数：2

共 50 条

[41] Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
Girgis, Suzette
Xin, Shun
Lin, Wang
Pillarisetti, Kodandaram
Verona, Raluca
Vieyra, Diego
Casneuf, Tineke
Fink, Damien
Miao, Xin
Chen, Yang
Stephenson, Tara
Banerjee, Arnob
Hilder, Brandi
Russell, Jeffery Scott
Smit, Jennifer
Goldberg, Jenna D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Weisel, Katja
Bueno, Orlando F.
Pothacamury, Rajvineeth K.
Freise, Kevin J.
Yue, Susan
Ross, Jeremy A.
Polepally, Akshanth R.
Talati, Chetasi
Lee, Shane
Jin, Ziyi
Buelow, Ben
Vij, Ravi
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +
[43] Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma
Peng, Fengping
Wang, Yuan
Zhao, Jiliang
Liu, Hui
Liu, Zhaoyun
Ding, Kai
Zhang, Hongkai
Fu, Rong
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 417 - 421
[44] Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
Mammadzadeh, Aytaj
Peng, Fulei
Atrash, Shebli
Hashmi, Hamza
Mohan, Meera
Alkharabsheh, Omar
Afrough, Aimaz
Cui, Wei
Mahmoudjafari, Zahra
Abdallah, Al-Ola
BLOOD, 2022, 140 : 4277 - 4278
[45] Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1
Sebag, Michael
Raje, Noopur S.
Bahlis, Nizar J.
Costello, Caitlin
Dholaria, Bhagirathbhai
Solh, Melhem
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Damore, Michael A.
Lon, Hoi Ken
Basu, Cynthia
Skoura, Athanasia
Chan, Edward
Trudel, Suzanne
Jakubowiak, Andrzej
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew P.
Lesokhin, Alexander
BLOOD, 2021, 138
[46] Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Mateos, Maria-Victoria
Chari, Ajai
Usmani, Saad Zafar
Goldschmidt, Hartmut
Weisel, Katja
Qi, Keqin
Londhe, Anil
Nair, Sandhya
Lin, Xiwu
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok V.
Slavcev, Mary
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[47] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
Costa, Luciano J.
Bahlis, Nizar J.
Usmani, Saad Z.
van de Donk, Niels W. C. J.
Nooka, Ajay K.
Perrot, Aurore
Qi, Keqin
Hodin, Caroline
Uhlar, Clarissa
Zuppa, Athena
Chastain, Katherine
Doyle, Margaret
Maria-Victoria, Mateos
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547
[48] Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Wang, Ying
Cao, Jiang
Gu, Weiying
Shi, Ming
Lan, Jianping
Yan, Zhiling
Jin, Lai
Xia, Jieyun
Ma, Sha
Liu, Yang
Li, Hujun
Pan, Bin
Chen, Wei
Fei, Xiaoming
Wang, Chunling
Xie, Xiaobao
Yu, Liang
Wang, Gang
Li, Huizhong
Jing, Guangjun
Cheng, Hai
Zhu, Feng
Sun, Haiying
Sang, Wei
Li, Depeng
Li, Zhenyu
Zheng, Junnian
Xu, Kailin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (20) : 2246 - +
[49] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Kumar, Shaji
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Bueno, Orlando F.
Ben Buelow
Freise, Kevin J.
Yue, Susan
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Vij, Ravi
BLOOD, 2021, 138
[50] Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab
Girgis, Suzette
Lin, Shun Xin Wang
Pillarisetti, Kodandaram
Verona, Raluca
Vieyra, Diego
Casneuf, Tineke
Fink, Damien
Miao, Xin
Chen, Yang
Stephenson, Tara
Banerjee, Arnob
Hilder, Brandi
Russell, Jeffery
Smit, Jennifer
Goldberg, Jenna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S39 - S40

← 1 2 3 4 5 →